John Guanjing Zhang’s Post

Has the amyloid hypothesis reached the end of its rope? ☑️Axios reports (link at end) that there is a sense that the amyloid hypothesis has reached a limit. ” of January, there were 127 drugs being assessed in 164 clinical trials against Alzheimer's, according to a study published in an Alzheimer's-focused journal. Three-quarters aim to modify the disease versus treat its symptoms, and a quarter were in Phase 3.Less than a fifth of total drugs under development — and 22% of those in Phase 3 trials — target amyloid.” ☑️The article goes on to say that some believe the newest product just approved has effects so minimal that patients may not notice. (Ah percentages are the devil you know.) But Lilly still may make Billions. ☑️ Why is there such a mismatch between value and price? Please don’t say hope or to quote  (better) critic, constant reader might frow up. Its the following: “pathologies affecting individuals’ identity have a distinctive significance in the perspective of valuing health in the sense that the ability to realize their identity by forming and pursuing goals and values is itself a constitutive aspect of well-being.” I see identity is the X factor in value like mortality. and the search continues because it must. link in comments https://lnkd.in/eygXFxuw

New Alzheimer's Drug: Hope for Better Brain Health #Alzheimersdrug #brainhealth #carefulregulation #clinicaltrialdata #CognitiveFunction #complexdiseases #FDA #Lilly #manufacturingprocess #newtreatments #qualitycontrolmeasures #solanezumab #stockprice

This new study is fascinating! Could weight-loss drugs like Ozempic be key to fighting Alzheimer’s? 🧠✨ New research offers a glimmer of hope. Read more here: #Alzheimers #HealthResearch #MedicalBreakthroughs #WeightLossDrugs #Ozempic #HopeForACure

In January 2024, a new clinical study was published in Nature’s Journal of Translational Medicine. It is titled “Tirzepatide prevents neurodegeneration through multiple molecular pathways”. Several pieces of evidence have demonstrated that glucagon-like peptide 1 receptor agonists (GLP1-RAs) reduce the risk of dementia in type 2 diabetes patients by improving memory, learning, and overcoming cognitive impairment. Likewise, in 2019, researchers in China and Taiwan published a study in the Journal of Parkinson's Disease investigating semaglutide and liraglutide in mice with conditions similar to Parkinson’s. They found that both drugs improved movement problems and protected brain cells. Semaglutide seemed to work better than liraglutide (GLP-1 receptor agonists). They decided to conduct a clinical study to investigate the neuroprotective effects of semaglutide. Scientists and clinicians have recognized the intimate connection between metabolic and mental well-being for centuries, echoing ancient wisdom. Insights from drug repurposing, like the unexpected benefits of Viagra for treating impotence after heart disease patients, have spurred scientists to explore novel applications and different use cases for existing medications. In this discussion, I aim to highlight two widely used glucagon-like peptide 1 receptor agonists, Tirzepatide and Semaglutide, to make my points. These drugs have the potential to affect the nervous, digestive, and immune systems positively. Their neuroprotective and anti-inflammatory properties make them promising candidates for repurposing in these areas. To better understand their potential, I want to explain the functions and mechanisms of glucagon-like peptide-1 across the body, including its impact on the brain. What is glucagon-like peptide-1? https://lnkd.in/g6VJK8bJ

Exploring the intricate roles of the endocannabinoid system and cannabinoids in health and disease. Dive into the latest research findings and the therapeutic potential of cannabinoids for conditions like inflammation, pain, and neurological disorders. #EndocannabinoidSystem #CannabinoidResearch #TherapeuticPotential For more detailed insights, you can read the full article here: https://lnkd.in/dAjjT4r3

Breakthrough study reveals the route cause of Alzheimer’s Disease: The researchers found that swelling caused by a byproduct of amyloid plaques may be the true cause of the disease's debilitating symptoms. They discovered that each formation of plaque can cause an accumulation of spheroid-shaped swellings along hundreds of axons, which are the thin cellular wires that connect the brain's neurons, near amyloid plaque deposits. The researchers discovered that a protein in lysosomes called PLD3 caused these organelles to grow and clump together along axons, eventually leading to the swelling of axons and the breakdown of electrical conduction. Their findings were published in the journal Nature. #alzheimers #alzheimersdisease #dementia #drugdiscovery #innovation #research #pharmaceuticals #medicalsciences #medicine #drugdevelopment Jaime Grutzendler

What if "sounding" out Alzheimer's was the answer? A new study uses targeted sound waves to break through the brain's barrier and deliver powerful anti-plaque drugs. The results? Promising! Dive into the science and the future of this potential game-changer: https://lnkd.in/gmhwtfPV #ultrasound #alzheimers #treatment #breakthrough #science #health #medicine

I News & Insights Exciting developments in Alzheimer's research! A new study presented at the AAIC suggests that Novo's GLP-1 drug liraglutide, known for treating diabetes and obesity, may also slow cognitive decline in Alzheimer's disease. The study found significant brain-protective effects, with nearly 50% less brain volume loss in key regions. Although further research is needed, this could be a promising step forward in the fight against Alzheimer's. At Akshar Global Clinical Research (AGCR) we are closely following these advancements that have the potential to change lives #AlzheimersResearch #ClinicalTrials #Neuroprotection #PharmaInnovation #AGCR #ClinicalResearch #CRO #ahmedabad

💊 Erectile dysfunction drugs like Viagra and Cialis may be linked to an 18% reduced risk of Alzheimer's. While promising, more trials are needed to confirm a potential connection. Interesting findings in the realm of men's health and cognitive function. #HealthyAging #ED #Alzheimer Read the article! https://loom.ly/vlvFQlo